Dozens of providers on this site withhold their prices. Valhalla Vitality is the first to put the policy in writing, explain the reasoning, and present it as something done for your benefit. That candour is genuinely unusual — and the reasoning does not survive much examination.
It Admits It Hides the Prices
The site poses the question itself and answers it: “Will I see specific medications or prices on this page? No.” — followed by “To reduce ‘hard advertising,’ we show detailed options and pricing only to patients inside the portal.” Product pages say “Sign in to view pricing & details.”
To learn what a month costs, you must create an account and complete a five to seven minute eligibility assessment. There is no way to compare Valhalla against any competitor without first becoming a registered lead.
Credit where it belongs: stating the policy is better than silently having it. Most sites that withhold pricing simply omit it and let you hunt. Valhalla tells you the hunt is futile and why, which at least saves you the time.
A Price List Is Not Advertising
The stated justification is reducing “hard advertising”. It is worth taking the argument seriously before rejecting it, because there is a real version of it: prices for these medications genuinely vary by dose, and a headline figure that turns out not to apply to you is its own kind of misleading. We have criticised exactly that elsewhere — the $49 that becomes $199, the $150 that only covers the titration doses. A company might reasonably decide it would rather show you a real number than a teaser.
But that argument supports publishing a range, or a table by dose, or a starting and maintenance figure. It does not support publishing nothing. And the framing inverts what advertising actually is: a price list is the least promotional thing a seller can put on a page. It is information that lets you leave. Marketing copy without prices is the advertising; the price is what constrains it.
The practical effect is a conversion funnel. Requiring registration and an assessment before disclosure means the company captures your contact details and medical information from everyone who merely wanted to know the cost — and it means the price is first shown to you at the moment you have already invested time and are furthest from comparison shopping. Whatever the intent, that is the mechanism.
For contrast, Ozari Health publishes $86 and $125 on the page, and Hone Health prices every drug and both membership tiers. Neither appears to have suffered from it.
The Accreditations Are Real
Valhalla cites three third-party credentials: LegitScript certification, NABP accreditation and HIPAA compliance.
The first two are worth something. LegitScript certifies that a healthcare or pharmacy merchant meets defined legitimacy and compliance standards, and NABP accredits pharmacy practice — both are externally verifiable, unlike the self-reported ratings and patient counts most of this category leans on.
This is a meaningfully different kind of claim from “4.9 stars from 25,000 patients”. An accreditation can be checked against the accreditor’s own register and can be revoked. In a market where compounded GLP-1 sellers have proliferated with little external scrutiny, choosing one that has submitted to any is a rational filter. HIPAA compliance is a legal baseline rather than an achievement, but the other two are real.
The compounding disclosure is also good: Valhalla states that “compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA”, and describes eligibility as depending on medical history and clinician assessment, adding that it “isn’t right for everyone”. Promising no commitments and no upfront medication decisions is the right posture too, particularly against the four-month minimums we have found elsewhere.
GLP-1 and GLP-1+
The products are named “GLP-1” and “GLP-1+”. No molecule is stated publicly — not semaglutide, not tirzepatide, not liraglutide.
“GLP-1+” most likely denotes a dual GLP-1 and GIP agonist, which would be tirzepatide, and the plain “GLP-1” a single agonist. But that is inference from a plus sign. The molecule determines everything about what you are buying: in their registration trials semaglutide produced roughly 15% mean weight loss, tirzepatide roughly 21%, and liraglutide roughly 8% as a daily rather than weekly injection.
Combined with the pricing policy, this means a prospective patient can learn neither what the medication is nor what it costs without registering. Those are the two facts that decide the purchase, and both sit behind the same door. The eligibility assessment is described as five to seven minutes, which is short for something that gates this much.
Provider Facts
| Medications offered | Products labelled GLP-1 and GLP-1+; underlying molecules are not named publicly |
|---|---|
| Brand-name or compounded | Compounded options offered, with a clear statement that compounded drug products are not approved or evaluated by the FDA for safety, effectiveness or quality |
| Consultation process | A five to seven minute online eligibility self-assessment, then licensed provider review |
| Eligibility | Stated as depending on medical history and clinician assessment, and as not right for everyone; no BMI threshold published |
| Provider involvement | Licensed provider reviews eligibility, with prescribing described as based on clinical necessity |
| Lab requirements | Not published |
| Pharmacy fulfillment | Not published; NABP accreditation cited |
| Shipping frequency | Not published |
| Support services | Not published in detail |
| Membership fees | Not published - shown only inside the patient portal |
| Medication fees | Not published - the site states pricing is shown only to patients inside the portal |
| Cancellation policy | Stated as no commitments and no upfront medication decisions; formal terms not published |
| Refund policy | Not published |
| Insurance | Coverage described as varying, with options discussed after eligibility |
| HSA/FSA | Not published |
| Availability | Not published - no state list found |
Pros and Cons
Pros
- LegitScript certification and NABP accreditation — externally verifiable credentials
- Clear statement that compounded products are not FDA-approved or evaluated
- Says outright that treatment is not right for everyone
- No commitments and no upfront medication decisions
- States its pricing policy explicitly rather than leaving you to hunt
- Short eligibility assessment with provider review before prescribing
Cons
- No pricing visible without creating an account and completing an assessment
- Never names the molecule behind “GLP-1” or “GLP-1+”
- Both key purchase facts sit behind the same registration wall
- Framing a withheld price list as reducing “hard advertising” inverts what advertising is
- No states, labs, pharmacy, shipping, refund or HSA/FSA detail
- Comparison shopping is impossible before handing over your details
Who It May Be Best For
Potentially suitable if third-party accreditation is your primary filter. LegitScript and NABP are real checks, and in a market this crowded with unaccredited compounded sellers that is a defensible way to narrow the field.
Do your comparison first. Establish what competitors charge for named molecules — our cheapest GLP-1 programs page is a starting point — then register here and see whether the portal price beats them. Going in without a benchmark means being shown a number you cannot evaluate.
Ask which molecule and what dose as soon as you are inside. “GLP-1+” is a product name, not a prescription.
Avoid if you are unwilling to hand over contact and medical details to find out a price. That is a legitimate position, and plenty of competitors will simply tell you.
Alternatives
Ozari Health names both molecules and both prices on the page. Curex publishes third-party testing alongside its pricing. Emerge Weight Loss quotes one all-in figure. Our best compounded GLP-1 providers page ranks this segment.
Limitations of This Review
Based on Valhalla Vitality’s own public pages at valhallavitality.com, checked on 6 September 2026. We did not create an account, so we have not seen the pricing or medication detail inside the portal — this review assesses what is available to someone deciding whether to register, which is the decision most readers face. Pricing figures appearing in the company’s blog articles are general market commentary rather than its own rates, and we have not treated them as such. Accreditation claims are the company’s own and can be checked against the accreditors’ registers. Trial figures for semaglutide, tirzepatide and liraglutide come from the published literature. Nothing here is medical advice.
Frequently Asked Questions
Why can I not see the prices?
Because Valhalla states it shows detailed options and pricing only to patients inside its portal, describing this as reducing “hard advertising”. You must register and complete a five to seven minute eligibility assessment first.
What is “GLP-1+”?
A product name rather than a drug name. The plus most likely indicates a dual GLP-1 and GIP agonist, which would be tirzepatide, but the site does not say. Ask for the molecule and dose.
Do LegitScript and NABP mean anything?
Yes. Both are third-party programmes with published standards and registers you can check, and both can be withdrawn. That makes them a materially different kind of claim from a self-reported star rating.
Is the medication FDA-approved?
Compounded options are offered, and Valhalla states plainly that compounded drug products are not approved or evaluated by the FDA for safety, effectiveness or quality.
Verdict
2.8 / 5 — pricing shown only after registration
Better external accreditation and a more candid compounding disclosure than most of this category, wrapped around a policy of telling you neither the drug nor the price until you have handed over your details — presented as a courtesy.
The point worth carrying beyond this provider: be sceptical when a company explains a withheld disclosure as being for your benefit. Publishing a price range costs nothing and helps buyers; requiring registration to see one helps the seller. When those two things are in tension, the stated reason matters less than which party the arrangement serves.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Valhalla Vitality's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026